{"id":78762,"date":"2026-09-04T16:04:48","date_gmt":"2026-09-04T08:04:48","guid":{"rendered":"https:\/\/flcube.com\/?p=78762"},"modified":"2026-09-04T16:04:49","modified_gmt":"2026-09-04T08:04:49","slug":"kanghongs-conbercept-wins-nmpa-approval-for-fifth-indication-in-retinopathy-of-prematurity-rop","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78762","title":{"rendered":"Kanghong\u2019s Conbercept Wins NMPA Approval for Fifth Indication in Retinopathy of Prematurity (ROP)"},"content":{"rendered":"\n

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773<\/a>)<\/strong> announced that China\u2019s National Medical Products Administration (NMPA)<\/strong> has approved a new indication for Conbercept Ophthalmic Injection<\/strong> in the treatment of retinopathy of prematurity (ROP)<\/strong>, specifically covering Zone I (stage 1+, 2+, 3, or 3+)<\/strong>, Zone II (stage 3+) ROP<\/strong>, and aggressive posterior ROP (AP-ROP)<\/strong>. The clearance marks the fifth approved indication<\/strong> for Kanghong\u2019s flagship Category 1 biologic drug<\/strong>, extending its reach from adult retinal diseases into pediatric ophthalmology.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/td>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr>
Approval Type<\/td>New indication approval<\/td><\/tr>
Product<\/td>Conbercept Ophthalmic Injection<\/strong><\/td><\/tr>
New Indication<\/td>Retinopathy of prematurity (ROP)<\/strong>: Zone I (stage 1+, 2+, 3, or 3+), Zone II (stage 3+), and aggressive posterior ROP (AP-ROP)<\/td><\/tr>
Date<\/td>03 Sept 2026<\/td><\/tr>
Next Steps<\/td>Commercialization of the ROP indication in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Approved Indications<\/h2>\n\n\n\n